O61 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients

Abstract

<h3>Background</h3> Despite the proven efficacy of biological treatments in Crohn’s disease (CD), many patients fail to respond or lose response over time. Therefore, predictive biomarkers for treatment efficacy would be...